Association Between MDM2 Promoter SNP309 T/G Polymorphism and Liver Cancer Risk - a Meta-analysis |
Ma, Hong-Bo
(Department of Hepatobiliary and Pancreatic Surgery, Henan Tumor Hospital, the Affiliated Tumor Hospital of Zhengzhou University)
Huang, Tao (Department of Hepatobiliary and Pancreatic Surgery, Henan Tumor Hospital, the Affiliated Tumor Hospital of Zhengzhou University) Han, Feng (Department of Hepatobiliary and Pancreatic Surgery, Henan Tumor Hospital, the Affiliated Tumor Hospital of Zhengzhou University) Chen, Wei-Yu (Department of Hepatobiliary and Pancreatic Surgery, Henan Tumor Hospital, the Affiliated Tumor Hospital of Zhengzhou University) |
1 | Hu Z, Jin G, Wang L, et al (2007). MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies. Cancer Epidemiol Biomark Prev, 16, 2717-23. DOI |
2 | Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. DOI |
3 | Jung CR, Lim JH, Choi Y, et al (2010). Enigma negatively regulates p53 through MDM2 and promotes tumor cell survival in mice. J Clin Invest, 120, 4493-506. DOI |
4 | Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48. |
5 | Kimman M, Norman R, Jan S, et al (2012). The Burden of Cancer in Member Countries of the Association of Southeast Asian Nations (ASEAN). Asian Pac J Cancer Prev, 13, 411-20. DOI |
6 | Lauria A, Tutone M, Ippolito M, et al (2010). Molecular modeling approaches in the discovery of new drugs for anti-cancer therapy: the investigation of p53-MDM2 interaction and its inhibition by small molecules. Curr Med Chem, 17, 3142-54. DOI |
7 | Leu JD, Lin IF, Sun YF, et al (2009). Association between MDM2-SNP309 and hepatocellular carcinoma in Taiwanese population. World J Gastroenterol, 15, 5592-7. DOI |
8 | Stroup DF, Berlin JA, Morton SC, et al (2000). Meta-analysis of observational studies in epidemiology. JAMA, 283, 2008. DOI |
9 | Muellerleile P, Mullen B (2006). Sufficiency and stability of evidence for public health interventions using cumulative meta-analysis. Am J Public Health, 96, 515-22. DOI |
10 | Stommel JM, Wahl GM (2005). A new twist in the feedback loop: stress-activated MDM2 destabilization is required for p53 activation. Cell Cycle, 4, 411-7. DOI |
11 | Wang B, Huang G, Wang D, et al (2010). Null genotypes of GSTM1 and GSTT1 contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis. J Hepatol, 53, 508-18. DOI ScienceOn |
12 | Wilkening S, Bermejo JL, Hemminki K (2007). MDM2 SNP309 and cancer risk: a combined analysis. Carcinogenesis, 28, 2262-7. DOI |
13 | Wang X, Zhang X, Qiu B, et al (2012). MDM2 SNP309T>G polymorphism increases susceptibility to hepatitis B virus-related hepatocellular carcinoma in a northeast Han Chinese population. Liver Int, 32, 1172-8. DOI |
14 | Whibley C, Pharoah PD, Hollstein M (2009). p53 polymorphisms: cancer implications. Nat Rev Cancer, 9, 95-107. DOI ScienceOn |
15 | Wiangnon S, Kamsa-Ard S, Suwanrungruang K, et al (2012). Trends in incidence of hepatocellular carcinoma, 1990 - 2009, Khon Kaen, Thailand. Asian Pac J Cancer Prev, 13, 1065-8. DOI ScienceOn |
16 | Bridges JF, Joy SM, Gallego G, et al (2011). Needs for hepatocellular carcinoma control policy in the Asia-Pacific region. Asian Pac J Cancer Prev, 12, 2585-91. |
17 | Yoon YJ, Chang HY, Ahn SH, et al (2008). MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis, 29, 1192-6. DOI ScienceOn |
18 | Zhang MF, Zhang ZY, Fu J, et al (2009). Correlation between expression of p53, p21/WAF1, and MDM2 proteins and their prognostic significance in primary hepatocellular carcinoma. J Transl Med, 7, 110. DOI |
19 | Zintzaras E, Lau J (2008). Synthesis of genetic association studies for pertinent gene-disease associations requires appropriate methodological and statistical approaches. J Clin Epidemiol, 61, 634-45. DOI |
20 | Akkiz H, Sumbul AT, Bayram S, et al (2010). MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population. Cancer Epidemiol, 34, 448-52. DOI |
21 | Chen WQ (2009). Estimation of cancer incidence and mortality in China in 2004-2005. Chin J Cancer, 31, 664-8. |
22 | Cheok CF, Verma CS, Baselga J, et al (2011). Translating p53 into the clinic. Nat Rev Clin Oncol, 8, 25-37. DOI |
23 | Dharel N, Kato N, Muroyama R, et al (2006). MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Clin Cancer Res, 12, 4867-71. DOI |
24 | Cochran WG (1954). The combination of estimates from different experiments. Biometrics, 10, 101-29. DOI |
25 | Deisenroth C, Zhang Y (2010). Ribosome biogenesis surveillance: probing the ribosomal protein-Mdm2-p53 pathway. Oncogene, 29, 4253-60. DOI |
26 | DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88. DOI |
27 | Economopoulos KP, Sergentanis TN (2010). Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis. Breast Cancer Res Treat, 120, 211-6. DOI |
28 | Di Vuolo V, Buonaguro L, Izzo F, et al (2011). TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patients. Infect Agent Cancer, 6, 13. DOI |
29 | Ding C, Yu H, Qin H (2012). TP53 Codon 72 Polymorphism with Hepatocellular Carcinoma: a Metaanalysis. J Int Med Res, 40, 446-54. DOI ScienceOn |
30 | Dongiovanni P, Fracanzani AL, Cairo G, et al (2010). Iron-dependent regulation of MDM2 influences p53 activity and hepatic carcinogenesis. Am J Pathol, 176, 1006-17. DOI |
31 | Egger M, Davey Smith G, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34. DOI |
32 | Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60. DOI ScienceOn |
33 | El-Serag HB (2011). Hepatocellular carcinoma. N Engl J Med, 365, 1118-27. DOI ScienceOn |
34 | Embade N, Fernandez-Ramos D, Varela-Rey M, et al (2012). Murine double minute 2 regulates Hu antigen R stability in human liver and colon cancer through NEDDylation. Hepatology, 55, 1237-48. DOI |
35 | Ezzikouri S, El Feydi AE, Afifi R, et al (2009). MDM2 SNP309T>G polymorphism and risk of hepatocellular carcinoma: a case-control analysis in a Moroccan population. Cancer Detect Prev, 32, 380-5. DOI |
36 | Ezzikouri S, Essaid El Feydi A, Afifi R, et al (2011). Impact of TP53 codon 72 and MDM2 promoter 309 allelic dosage in a Moroccan population with hepatocellular carcinoma. Int J Biol Markers, 26, 229-33. |
37 | Fang F, Yu XJ, Yu L, et al (2011). MDM2 309 T/G polymorphism is associated with colorectal cancer risk especially in Asians: a meta-analysis. Med Oncol, 28, 981-5. DOI |
38 | Forner A, Llovet JM, Bruix J (2012). Hepatocellular carcinoma. Lancet, 379, 1245-55. DOI |
39 | Gajjar M, Candeias MM, Malbert-Colas L, et al (2012). The p53 mRNA-Mdm2 interaction controls Mdm2 nuclear trafficking and is required for p53 activation following DNA damage. Cancer Cell, 21, 25-35. DOI ScienceOn |